Cargando…

Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP

PURPOSE: Our aims were to investigate the pathogenesis of diabetic cardiomyopathy (DCM) and to explore the protective effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) on DCM. METHODS: After 12 weeks of treatment with exenatide-loaded microspheres, a long-acting GLP-1RA, in DCM mice, card...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Ping, Ye, Zhengqin, Li, Ran, She, Dunmin, Zong, Guannan, Zhang, Liya, Xue, Ying, Zhang, Keqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019346/ https://www.ncbi.nlm.nih.gov/pubmed/36936522 http://dx.doi.org/10.2147/DDDT.S400249

Ejemplares similares

Glucagon-Like Peptide 1 Receptor Agonist Improves Renal Tubular Damage in Mice with Diabetic Kidney Disease
por: Li, Ran, et al.
Publicado: (2022)

Serum osteocalcin level is associated with the mortality in Chinese patients with Fibrodysplasia ossificans progressiva aged ≤18 years at diagnosis
por: She, Dunmin, et al.
Publicado: (2020)

Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6
por: Li, Ran, et al.
Publicado: (2022)

Hydrophobic profiles of the tail anchors in SLMAP dictate subcellular targeting
por: Byers, Joseph T, et al.
Publicado: (2009)

SLMAP3 isoform modulates cardiac gene expression and function
por: Mlynarova, Jana, et al.
Publicado: (2019)

Targeting SLMAP-ALK—a novel gene fusion in lung adenocarcinoma
por: Pagan, Carlos, et al.
Publicado: (2019)

Role of SLMAP genetic variants in susceptibility of diabetes and diabetic retinopathy in Qatari population
por: Upadhyay, Rohit, et al.
Publicado: (2015)

Correlation of multiple lipid and lipoprotein ratios with nonalcoholic fatty liver disease in patients with newly diagnosed type 2 diabetic mellitus: A retrospective study
por: Li, Ran, et al.
Publicado: (2023)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Conformation Transition of Intracellular Part of Glucagon Receptor in Complex With Agonist Glucagon by Conventional and Accelerated Molecular Dynamics Simulations
por: Bai, Qifeng, et al.
Publicado: (2019)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy
por: Liu, Yamin, et al.
Publicado: (2019)

Increased Expression of the Tail-Anchored Membrane Protein SLMAP in Adipose Tissue from Type 2 Tally Ho Diabetic Mice
por: Chen, Xiaoliang, et al.
Publicado: (2011)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
por: Lorenz, Martin, et al.
Publicado: (2017)

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
por: Madsbad, Sten
Publicado: (2015)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
por: Choe, Hun Jee, et al.
Publicado: (2021)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
por: Baggio, Laurie L., et al.
Publicado: (2020)

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021)

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
por: Patel Chavez, Chandani, et al.
Publicado: (2021)

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
por: Lisco, Giuseppe, et al.
Publicado: (2023)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
por: Eriksson, Olof, et al.
Publicado: (2020)

Association of Serum Periostin Level with Classical Bone Turnover Markers and Bone Mineral Density in Shanghai Chinese Postmenopausal Women with Osteoporosis
por: Li, Ran, et al.
Publicado: (2021)

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
por: Unger, Jeffrey R., et al.
Publicado: (2011)

The Effect of Glucagon-Like Peptide-2 Receptor Agonists on Colonic Anastomotic Wound Healing
por: Redstone, Heather A., et al.
Publicado: (2010)

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
por: Hong, Yeonhee, et al.
Publicado: (2019)

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
por: Almandoz, Jaime P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sgftnlhls4g6fh0lvgl4odh57b